[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Bullish Analyst Recommendation - Leerink 10/15 🧬📈 $NTLA $XX - Outperform $CRBU $X - Outperform $BEAM $XX - Outperform $CRSP $XX - Outperform"
X Link @CrisprGlenn 2025-10-15T13:22Z 2699 followers, 1920 engagements
"After Hours Smallcaps ($200M-2B) - Oct XX Gainers Losers $VERI +52% $SOC -XX% $PZZA +13% $NVA -XX% $IRWD +11% $TMQ -XX% $HOND +9.7% $NGNE -X% $NKTR +9.5% $ASPI -XXX% $NPWR +8.5% $NEWP -XXX% $COHU +8% $EYPT -X% $GEVO +7.8% $RBBN -XXX% $MNTK +6.5% $JCAP -XXX% $CRESY +6.4% $CRBU -XXX% $NKLR +6.2% $KARO -XXX% $AMCX +6% $AREC -X% $HCKT +5.9% $IONR -X% $BZAI +5.6% $OMDA -XXX% $WLAC +5.2% $NVX -3.8%"
X Link @MarketCap_Live 2025-10-14T23:31Z XXX followers, 2023 engagements
"Here's your Morning CRISPR Brief ☕☀ Recap: gene editing stocks dipped 3-9% on Oct. 10th amid broader market weakness but fundamentals remain intact $CRSP -XXXX% $SANA -XXXX% $NTLA -XXXX% $BEAM -XXXX% $EDIT -XXXX% $PRME -XXXX% $CRBU -9.45%. Big Pharmas interest in CRISPR is heating up again 🔥 as evidenced by several partnerships and deals just last week. The unveiling of a next-gen platform like SyNTase and good poc data reflects steady momentum in the gene editing sector. Some highlights from last week: 1) Non-dilutive win for @BeamTx: $BMY acquired Orbital Therapeutics BEAM's RNA"
X Link @3primeAnalytica 2025-10-13T13:17Z 1272 followers, 2862 engagements
"This is great for $CRBU and all the other great gene therapy companies love this. (Equivalent value for Caribou would be $15/share) Bristol-Myers buys Orbital Therapeutics"
X Link @dadbodfamilyguy 2025-10-10T13:30Z XXX followers, XXX engagements